By Bernadette Toner and Turna Ray
SAN FRANCISCO — A Novartis official said yesterday that the company has identified a genetic marker that it plans to market as a companion diagnostic for a COX-2 inhibitor that was previously withdrawn from several non-US markets due to liver toxicity issues.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.
A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.
A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.
The BabySeq project to study the risks and benefits of sequencing newborns is underway.